These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 27023686)

  • 41. Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients.
    van de Laar CJ; Janssen CA; Janssen M; Oude Voshaar MAH; Al MJ; van de Laar MAFJ
    PLoS One; 2022; 17(1):e0261940. PubMed ID: 35089941
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease.
    Huang HH; Chen YY; Fang YW; Liou HH; Wang JT; Tsai MH
    Med Sci Monit; 2024 Jun; 30():e944314. PubMed ID: 38865287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of Chronic Kidney Disease With Allopurinol Use in Gout Treatment.
    Vargas-Santos AB; Peloquin CE; Zhang Y; Neogi T
    JAMA Intern Med; 2018 Nov; 178(11):1526-1533. PubMed ID: 30304329
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data.
    Singh JA; Cleveland JD
    Ann Rheum Dis; 2017 Oct; 76(10):1669-1678. PubMed ID: 28584186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Febuxostat for treating chronic gout.
    Tayar JH; Lopez-Olivo MA; Suarez-Almazor ME
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008653. PubMed ID: 23152264
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers.
    Juge PA; Truchetet ME; Pillebout E; Ottaviani S; Vigneau C; Loustau C; Cornec D; Pascart T; Snanoudj R; Bailly F; Cornec-Le Gall E; Schaeverbeke T; Saraux A; Dieudé P; Flipo RM; Richette P; Lioté F; Bardin T; Chalès G; Ea HK
    Joint Bone Spine; 2017 Oct; 84(5):595-598. PubMed ID: 27825577
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diabetes and gout: efficacy and safety of febuxostat and allopurinol.
    Becker MA; MacDonald PA; Hunt BJ; Jackson RL
    Diabetes Obes Metab; 2013 Nov; 15(11):1049-55. PubMed ID: 23683134
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases
.
    Yang AY
    Int J Clin Pharmacol Ther; 2020 Jan; 58(1):21-28. PubMed ID: 31657714
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M; Cimmino MA; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
    Becker MA; Schumacher HR; Espinoza LR; Wells AF; MacDonald P; Lloyd E; Lademacher C
    Arthritis Res Ther; 2010; 12(2):R63. PubMed ID: 20370912
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3.
    Novella-Navarro M; Cabrera-Alarcon JL; Diaz-Torne C; Aramburu-Muñoz F; Janta I; Ortega de la O MC; Prada-Ojeda A; Sala-Icardo L; Urruticoechea-Arana A; García de la Peña Lefebvre P; Calvo-Aranda E
    Rheumatol Int; 2020 Jul; 40(7):1081-1087. PubMed ID: 31982955
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis.
    Borghi C; Perez-Ruiz F
    Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):983-92. PubMed ID: 27010159
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease : A Population-Based Cohort Study.
    Wei J; Choi HK; Neogi T; Dalbeth N; Terkeltaub R; Stamp LK; Lyu H; McCormick N; Niu J; Zeng C; Lei G; Zhang Y
    Ann Intern Med; 2022 Apr; 175(4):461-470. PubMed ID: 35073156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China.
    Cheng H; Yan D; Zuo X; Liu J; Liu W; Zhang Y
    Pharmacogenet Genomics; 2018 May; 28(5):117-124. PubMed ID: 29642234
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
    Quilisadio JEC; Salido EO; Penserga EG
    Mod Rheumatol; 2021 May; 31(3):755-761. PubMed ID: 32701037
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.
    Wu EQ; Forsythe A; Guérin A; Yu AP; Latremouille-Viau D; Tsaneva M
    Am J Ther; 2012 Nov; 19(6):e157-66. PubMed ID: 21317625
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis.
    Kim SH; Lee SY; Kim JM; Son CN
    Korean J Intern Med; 2020 Jul; 35(4):998-1003. PubMed ID: 30959584
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of an adherence-enhancing intervention for gout based on real-world data.
    Lin LW; Teng GG; Lim AYN; Yoong JS; Zethraeus N; Wee HL
    Int J Rheum Dis; 2019 Apr; 22(4):545-554. PubMed ID: 30556300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.